Affordable Access

Access to the full text

The legalization of cannabinoid products and standardizing cannabis-drug development in the United States: a brief report

Authors
  • Marcu, Jahan
Type
Published Article
Journal
Dialogues in Clinical Neuroscience
Publisher
Les Laboratoires Servier
Publication Date
Sep 01, 2020
Volume
22
Issue
3
Pages
289–293
Identifiers
DOI: 10.31887/DCNS.2020.22.3/jmarcu
PMID: 33162772
PMCID: PMC7605018
Source
PubMed Central
Keywords
License
Green

Abstract

This brief report covers recent advances in cannabis and cannabinoid regulation and drug approval. The popularity of cannabis and cannabinoid products continues to rise, and these products are available for the majority of the population in the United States to purchase as easily as alcohol. Although many states have approved programs and research licenses, these activities and products all remain federally illegal. The solution may be for the United States to offer multiple pathways for product approval that adapt to the diversity of the products and the needs of the consumer. Multiple pathways for market approval would protect public health, whether the public is using cannabis and cannabinoids as a medicine, a wellness product, or as a recreational substance.

Report this publication

Statistics

Seen <100 times